Systematic review of the accuracy of plasma preparation tubes for HIV viral load testing


Autoři: Robert Luo aff001;  Jessica Markby aff002;  Jilian Sacks aff002;  Lara Vojnov aff001
Působiště autorů: World Health Organization, Geneva, Switzerland aff001;  Clinton Health Access Initiative, Boston, Massachusetts, United States of America aff002
Vyšlo v časopise: PLoS ONE 14(11)
Kategorie: Research Article
doi: 10.1371/journal.pone.0225393

Souhrn

Expanding access to HIV viral load testing is essential to improving the care and treatment of people living with HIV/AIDS and ending the AIDS epidemic. Though significant investments have been made in the past five years, many high burden, low resource countries continue to have viral load access rates below 50%. Plasma preparation tubes (PPTs) can simplify storage, transport, and preparation of plasma used for viral load testing. A systematic review was conducted to evaluate the accuracy of plasma preparation tubes for HIV viral load testing. Study results regarding the accuracy of PPT viral load measurements across various storage and transportation conditions were examined. The quality of evidence was evaluated using GRADE and QUADAS-2 criteria. The review identified 16 studies using PPTs with data from 6,141 individuals from 1995 to 2014. Overall the quality of evidence was rated as moderate, with unclear applicability for studies evaluating viral load assays that are no longer commercially available. Significantly elevated viral load results (>0.3 log copies/ml difference) have been observed with PPTs; however, when manufacturer handling instructions are followed, when plasma is aliquoted into a secondary tube, or when PPTs are centrifuged prior to testing, PPT results only differed from standard EDTA plasma testing using commercially available viral load assays by a range on average of -0.03 to +0.08 log copies/ml across studies. Although spuriously elevated viral load results have been observed with PPTs, following proper sample handing techniques have been shown to provide accurate results. PPTs, therefore, provide a high quality alternative specimen type for countries seeking solutions to infrastructure and specimen transportation challenges in an effort to scale-up viral load testing and achieve 90-90-90 targets.

Klíčová slova:

Blood – Blood plasma – Centrifugation – HIV-1 – Systematic reviews – United States – Viral load


Zdroje

1. World Health Organization. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach. 2nd ed. Geneva: World Health Organization. 2016.

2. UNAIDS. 90-90-90: An ambitious treatment target to help end the AIDS epidemic. Geneva: UNAIDS. 2014.

3. World Health Organization. Technical and operational considerations for implementing HIV viral load testing. Geneva: World Health Organization. 2014.

4. Médecins Sans Frontières. Putting HIV and HCV to the test: a product guide for point-of-care CD4 and laboratory-based and point-of-care HIV and HCV viral load tests. Geneva: MSF. 2017.

5. Habiyambere V, Dongmo Nguimfack B, Vojnov L, Ford N, Stover J, Hasek L, et al. Forecasting the global demand for HIV monitoring and diagnostic tests: A 2016–2021 analysis. PLoS One. 2018 Sep 19;13(9):e0201341. doi: 10.1371/journal.pone.0201341 30231022

6. Clinton Health Access Initiative. HIV market report. Boston: CHAI. 2018. Available from https://clintonhealthaccess.org/content/uploads/2018/09/2018-HIV-Market-Report_FINAL.pdf

7. Smit PW, Sollis KA, Fiscus S, Ford N, Vitoria M, Essajee S, et al. Systematic review of the use of dried blood spots for monitoring HIV viral load and for early infant diagnosis. PLoS One. 2014 Mar 6;9(3):e86461. doi: 10.1371/journal.pone.0086461 24603442

8. Becton, Dickinson, and Company. BD Vacutainer® PPT Instructions for Use. 2015. Available from https://www.bdbiosciences.com/ds/ab/others/PI_PPT_March_2016_VDP40162-03_Web.pdf

9. Bonner K, Siemieniuk RA, Boozary A, Roberts T, Fajardo E, Cohn J. Expanding access to HIV viral load testing: A systematic review of RNA stability in EDTA tubes and PPT beyond current time and temperature thresholds. PLoS One. 2014 Dec 1;9(12):e113813. doi: 10.1371/journal.pone.0113813 25437009

10. Moher D, Liberati A, Teztlaff J, Altman DG, PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PloS Med. 2009;6:e1000097. doi: 10.1371/journal.pmed.1000097 19621072

11. Whiting PF, Rutjes AW, Westwood ME, Mallett S, Deeks JJ, Reitsma JB, et al. QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med. 2011;155:529–536. doi: 10.7326/0003-4819-155-8-201110180-00009 22007046

12. Schünemann HJ, Oxman AD, Brozek J, Glasziou P, Jaeschke R, Vist GE, et al. Grading quality of evidence and strength of recommendations for diagnostic tests and strategies. BMJ. 2008;336:1106–1110. doi: 10.1136/bmj.39500.677199.AE 18483053

13. Holodniy M, Mole L, Yen-Lieberman B, Margolis D, Starkey C, Carroll R, et al. Comparative stabilities of quantitative human immunodeficiency virus RNA in plasma from samples collected in VACUTAINER CPT, VACUTAINER PPT, and standard VACUTAINER tubes. J Clin Microbiol. 1995 Jun;33(6):1562–6. 7650187

14. Ginocchio CC, Wang XP, Kaplan MH, Mulligan G, Witt D, Romano JW, et al. Effects of specimen collection, processing, and storage conditions on stability of human immunodeficiency virus type 1 RNA levels in plasma. J Clin Microbiol. 1997 Nov;35(11):2886–93. 9350753

15. Holodniy M, Rainen L, Herman S, Yen-Lieberman B. Stability of plasma human immunodeficiency virus load in VACUTAINER PPT plasma preparation tubes during overnight shipment. J Clin Microbiol. 2000 Jan;38(1):323–6. 10618109

16. Elbeik T, Nassos P, Kipnis P, Haller B, Ng VL. Evaluation of the VACUTAINER PPT Plasma Preparation Tube for use with the Bayer VERSANT assay for quantification of human immunodeficiency virus type 1 RNA. J Clin Microbiol. 2005 Aug;43(8):3769–71. doi: 10.1128/JCM.43.8.3769-3771.2005 16081908

17. Giordano M, Kelleher T, Colonno RJ, Lazzarin A, Squires K. The effects of the Roche AMPLICOR HIV-1 MONITOR UltraSensitive Test versions 1.0 and 1.5 viral load assays and plasma collection tube type on determination of response to antiretroviral therapy and the inappropriateness of cross-study comparisons. J Clin Virol. 2006 Apr;35(4):420–5. 16604577

18. Griffith BP, Mayo DR. Increased levels of HIV RNA detected in samples with viral loads close to the detection limit collected in Plasma Preparation Tubes (PPT). J Clin Virol. 2006 Feb;35(2):197–200. 16253548

19. Wan H, Seth A, Rainen L, Fernandes H. Coamplification of HIV-1 proviral DNA and viral RNA in assays used for quantification of HIV-1 RNA. J Clin Microbiol. 2010 Jun;48(6):2186–90. doi: 10.1128/JCM.02034-09 20181913

20. Salimnia H, Moore EC, Crane LR, Macarthur RD, Fairfax MR. Discordance between viral loads determined by Roche COBAS AMPLICOR human immunodeficiency virus type 1 monitor (version 1.5) Standard and ultrasensitive assays caused by freezing patient plasma in centrifuged becton-dickinson vacutainer brand plasma preparation tubes. J Clin Microbiol. 2005 Sep;43(9):4635–9. doi: 10.1128/JCM.43.9.4635-4639.2005 16145119

21. García-Bujalance S, Ladrón de Guevara C, González-García J, Arribas JR, Zamora F, Gutiérrez A. Elevation of viral load by PCR and use of plasma preparation tubes for quantification of human immunodeficiency virus type 1. J Microbiol Methods. 2007 May;69(2):384–6. doi: 10.1016/j.mimet.2007.01.018 17363096

22. Rebeiro PF, Kheshti A, Bebawy SS, Stinnette SE, Erdem H, Tang YW, et al. Increased detectability of plasma HIV-1 RNA after introduction of a new assay and altered specimen-processing procedures. Clin Infect Dis. 2008 Nov 15;47(10):1354–7. doi: 10.1086/592693 18922071

23. Kran AM, Jonassen TØ, Sannes M, Jakobsen K, Lind A, Maeland A, et al. Overestimation of human immunodeficiency virus type 1 load caused by the presence of cells in plasma from plasma preparation tubes. J Clin Microbiol. 2009 Jul;47(7):2170–4. doi: 10.1128/JCM.00519-09 19420166

24. Kraft CS, Binongo JN, Burd EM, Eaton ME, McCloskey CB, Fernandes H, et al. Successful use of Plasma Preparation Tubes™ (PPTs) in the COBAS® AmpliPrep/COBAS® TaqMan® HIV-1 test. J Clin Virol. 2013 May;57(1):77–9. doi: 10.1016/j.jcv.2012.12.015 23332979

25. Fernandes H, Morosyuk S, Abravaya K, Ramanathan M, Rainen L. Evaluation of effect of specimen-handling parameters for plasma preparation tubes on viral load measurements obtained by using the Abbott RealTime HIV-1 load assay. J Clin Microbiol. 2010 Jul;48(7):2464–8. doi: 10.1128/JCM.00083-10 20484602

26. Adachi D, Benedet M, Tang JW, Taylor GD. Comparative evaluation of Roche's COBAS Ampliprep/COBAS TaqMan HIV-1 Test v2.0 and Abbott's RealTime m2000sp/rt HIV-1 assay on PPTs and EDTA samples. J Clin Virol. 2014 May;60(1):78–9. doi: 10.1016/j.jcv.2014.01.019 24594081

27. Cloherty G, Swanson P, Lucic D, Dieckhaus K, Anthony P, Cataline P, et al. Clinical implications of elevated HIV-1 viral load results obtained from samples stored frozen in vacutainer plasma preparation tubes. J Virol Methods. 2014 Aug;204:91–2. doi: 10.1016/j.jviromet.2014.01.025 24747107

28. Goedhals D, Scott LE, Moretti S, Cooper MA, Opperman WJ, Rossouw I. Evaluation of the use of plasma preparation tubes for HIV viral load testing on the COBAS AmpliPrep/COBAS TaqMan HIV-1 version 2.0. J Virol Methods. 2013 Feb;187(2):248–50. doi: 10.1016/j.jviromet.2012.11.019 23178587

29. Sollis KA, Smit PW, Fiscus S, Ford N, Vitoria M, Essajee S, et al. Systematic review of the performance of HIV viral load technologies on plasma samples. PLoS One. 2014 Feb 18;9(2):e85869. doi: 10.1371/journal.pone.0085869 24558359

30. Modjarrad K, Chamot E, Vermund SH. Impact of small reductions in plasma HIV RNA levels on the risk of heterosexual transmission and disease progression. AIDS. 2008 Oct 18;22(16):2179–85. doi: 10.1097/QAD.0b013e328312c756 18832881

31. Becton, Dickinson, and Company. BD White Paper VS8188: Evaluation Of The Effect Of Specimen Handling Conditions In BD Vacutainer® PPT On The Stability Of HIV-1 Viral Load Using Roche Cobas® Ampliprep/Cobas® Taqman® HIV-1 Test. 2010. Available from https://cbpwhitepapers.bd.com/bdvacutainerppttube.aspx

32. Becton, Dickinson, and Company. BD White Paper VS8189: Evaluation of Specimen Handling Conditions in BD Vacutainer® Plasma Preparation Tube HIV-1 Viral Load as Measured by the Abbott RealTime HIV-1 Assay. 2010. Available from https://cbpwhitepapers.bd.com/bdvacutainerppttube.aspx

33. Sabino EC, Gaburo N Jr, Leite JP, Viecili M, Rosenfeld LG. Platelets may affect detection and quantitation of HIV RNA in plasma samples with low viral loads. J Acquir Immune Defic Syndr. 2004 Nov 1;37(3):1432–3. doi: 10.1097/00126334-200411010-00013 15483474

34. Lee TH, Stromberg RR, Heitman JW, Sawyer L, Hanson CV, Busch MP. Distribution of HIV type 1 (HIV-1) in blood components: detection and significance of high levels of HIV-1 associated with platelets. Transfusion. 1998 Jun;38(6):580–8. doi: 10.1046/j.1537-2995.1998.38698326338.x 9661692

35. Greiner Bio-One. Evaluation of VACUETTE® K2EDTA Gel Tubes for Molecular Diagnostics. 2009. Available from https://www.gbo.com/fileadmin/user_upload/Downloads/White_Papers/WP_Evaluation_K2Gel_USA09_Rev00.pdf

36. TUD. Products Description: K2 EDTA with Gel Tubes. 2010. Available from http://www.tud.my/file/TUD_Leaflet_K2EDTA%20Gel_White_R1_FAol.pdf

37. WHO Prequalification of Diagnostics Programme. Public Report: Xpert® HIV-1 Viral Load. 2017. Available at https://www.who.int/diagnostics_laboratory/evaluations/pq-list/hiv-vrl/170830_amended_final_pqpr_0192_0193_0194_0195_070_00_v3.pdf?ua=1

38. WHO Prequalification of Diagnostics Programme. Public Report: AptimaTM HIV-1 Quant Dx Assay. 2018. Available at https://www.who.int/diagnostics_laboratory/evaluations/pq-list/180207_final_pqpr_0236_078_00_v5_IFU_v4.pdf?ua=1


Článek vyšel v časopise

PLOS One


2019 Číslo 11